Unraveling the topological architecture and phenotypic contexture of structural variation
Unraveling the topological architecture and phenotypic contexture of structural variation
批准号:
10356208
负责人:
Marcin Piotr Cieslik
金额:
$29.7万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-22 至 2023-09-21
关键词:
3-DimensionalAddressAdoptionAdultArchitectureAutomobile DrivingBiologicalCancer PatientChromatinChromosome abnormalityCicatrixClinicalCommunitiesCopy Number PolymorphismDNA Sequence RearrangementDataData SetEnhancersEpigenetic ProcessFoundationsFundingGene ExpressionGene Expression ProfileGeneticGenomeGenomic InstabilityGenomic medicineGenomicsGenotypeHumanIndividualKnowledgeLinkMalignant Childhood NeoplasmMalignant NeoplasmsMedicalMethodologyMethodsNeoplasm MetastasisNuclearPathogenicityPatientsPhenotypePrimary NeoplasmRecurrenceRefractoryRegulatory ElementResearchResourcesRoleSamplingStatistical ModelsStructural ModelsStructureTestingTimeTissue-Specific Gene ExpressionTissuesVariantcancer genomecancer typedata integrationdata resourceepigenomicsfunctional genomicsgenetic informationgenome sequencinggenomic datainsightmolecular phenotypenoveloncology programphenotypic dataprecision oncologypredictive modelingpredictive toolsprogramsproteogenomicstooltumorweb portalwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The increasing adoption of whole-genome sequencing (WGS) in the context of genomic medicine and
precision oncology has resulted in the accelerated discovery of structural variants (SVs) in patient
cancer genomes. However, while human cancer types are generally characterized by widespread
genomic instability the functional consequences of most structural and copy number variants (CNV)
remain poorly understood. Critically, it is unknown which of the hundreds to thousands of
genomic rearrangements typically observed in a patient tumor are pathogenic and which are non-
functional genomic scars. Because SVs alter the genome at the structural (linear sequence),
topological (three-dimensional organization), and phenotypic levels (epigenetic landscape),
integrative and multiscale datasets are necessary to correctly predict their impact. This dearth of
integrative resources and tools critically limits the medical interpretation of patient genetic data.
Existing large-scale genomic and proteogenomic cancer characterization efforts, including the
Common Fund (CF) Gabriella Miller Kids First (GMKF) data resource provide rich data to link
genetic information including SVs with their phenotypic consequences, such as gene expression.
However, these datasets alone are insufficient to provide deep mechanistic and functional insights.
CF data sets, specifically 4D Nucleome (4DN), Epigenomics (Roadmap), and GTEx provide the
blueprint to link germline variation, genome topology, and chromatin architecture to gene expression.
Therefore, we propose the integration of genomic data from patient tumor samples (GMKF), with
spatial and functional data (4DN, Roadmap, GTEx), which will allow us to elucidate and predict the
pathogenic mechanisms of structural variants:
Aim 1: To create TopVar a data resource to enhance our understanding of the interplay between
genome TOPology and structural VARiation. The integrative TopVar resource will provide the
phenotypic context required to interpret SVs in genetic and biological terms, which will yield testable
hypotheses regarding their downstream effects.
Aim 2: To develop and evaluate a predictive model of SV pathogenicity across multiple human cancers.
Using the structured TopVar data resource, we will implement an interpretable statistical model to
predict which SVs have an impact on gene expression, utilizing multiple layers of the integrated data.
The realization of both aims will represent a proof-of-principle for the utility of TopVar for predictive
modeling of SVs in the context of precision oncology. While our proposed study will focus
on interrogating the comprehensive genomic data generated by GMKF (pediatric cancer) and
CPTAC (adult cancer), it will serve as the foundation for their use within real-time sequencing
programs, such as MI-OncoSeq and Peds-MI-OncoSeq, focusing on refractory and metastatic tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金